News
SHRXF
1.580
NaN%
--
Sharp Therapeutics posts preclinical data on small-molecule Niemann-Pick type C drug approach
PUBT · 05/28 20:05
SHARP THERAPEUTICS PRESENTS NEW PRECLINICAL DATA SUPPORTING NOVEL SMALL-MOLECULE THERAPEUTIC APPROACH FOR NIEMANN-PICK DISEASE TYPE C
Reuters · 05/28 20:00
Sharp Therapeutics shifts Gaucher, GBA1 Parkinson’s programs to alternative lead compound
Reuters · 04/10 21:17
Sharp Therapeutics drops '901 candidate, advances alternative for Gaucher and GBA1 Parkinson's
Reuters · 04/10 21:05
Sharp Therapeutics closes fourth tranche of US$200,000 convertible notes offering
Reuters · 04/10 21:01
Sharp Therapeutics Closes US$500,000 Unsecured Convertible Note Tranche
Reuters · 02/27 22:22
Sharp Therapeutics Launches US$3 Million Unsecured Convertible Notes Offering
Reuters · 02/02 17:10
Sharp Therapeutics Appoints Robin Ely, M.D., to Advisory Board
Reuters · 01/27 17:09
Sharp Therapeutics Corp. (TSX-V: SHRX) Trading Resumes After Halt, Announces CIRO
Reuters · 10/14/2025 15:40
Sharp Therapeutics Corp. (TSX-V: SHRX) Trading Halted by CIRO Pending News
Reuters · 10/14/2025 15:28
Weekly Report: what happened at SHRXF last week (0908-0912)?
Weekly Report · 09/15/2025 12:40
Weekly Report: what happened at SHRXF last week (0901-0905)?
Weekly Report · 09/08/2025 12:41
Weekly Report: what happened at SHRXF last week (0825-0829)?
Weekly Report · 09/01/2025 12:34
More
Webull provides a variety of real-time SHRXF stock news. You can receive the latest news about Sharp Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About SHRXF
Sharp Therapeutics Corp. is a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases. Its discovery platform combines high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. Its technology includes CoreX assay technology, AlloChem compound libraries, and mine data system and machine learning layer. Its advanced programs include a small molecule that prevents the degradation of the neuroprotective protein progranulin, thus increasing progranulin levels preventing neurodegeneration, and a small molecule that restores activity of mutated GCase protein (mutation and loss of activity of GCase is the genetic cause of Gaucher’s disease).